MedPath

Assessment of Invasive Mediastinal Staging in cN1 Lung Cancer.

Not Applicable
Active, not recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
Procedure: Thoracic endosonography
Registration Number
NCT01456429
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Brief Summary

This is a prospective non-randomized multicenter clinical trial performing endobronchial and esophageal ultrasound for mediastinal lymph node staging of operable and resectable cT1-T2-selectedT3 cN1 cM0 NSCLC.

Detailed Description

Provided no mediastinal lymph node metastases are proven by echoendoscopy, all patients will subsequently undergo surgical staging. Patients without tissue proof of mediastinal nodal disease at surgical staging will undergo a thoracotomy with systematic lymph node dissection. Provided mediastinal lymph node metastases are proven by echoendoscopy, the patient goes off study protocol and can further be assessed/treated according to local clinical practice.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Patients with operable and resectable (suspected) NSCLC
  • Patients with clinical N1 staging based on PET/CT
  • Only T1, T2, and selected T3 (i.e. intraparenchymal tumour >7cm, chest wall, or additional nodule in the same lobe) are allowed.
Exclusion Criteria
  • Patients with enlarged mediastinal lymph nodes on chest CT or FDG-PET positive mediastinal lymph nodes
  • Patients with a central tumour staged T3 or any T4.
  • All stage IV patients.
  • Patient unable to give informed consent.
  • Patient previously underwent a mediastinoscopy.
  • Tracheal or upper airway stenosis.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Thoracic endosonographyThoracic endosonographyEndobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
Primary Outcome Measures
NameTimeMethod
Sensitivity of echo-endoscopic mediastinal staging in operable and resectable cT1-2-selectedT3 cN1 NSCLCOne month
Secondary Outcome Measures
NameTimeMethod
Cost-effectiveness analysis for echo-endoscopy in cN1 disease NSCLCone month
NPV of echo-endoscopic mediastinal staging in operable and resectable cT1-2-selectedT3 cN1 NSCLCone month

Trial Locations

Locations (3)

Universitair Ziekenhuis Gent

🇧🇪

Gent, Belgium

Radboud University Nijmegen Medical Centre

🇳🇱

Nijmegen, Netherlands

Universitaire Ziekenhuizen leuven

🇧🇪

Leuven, Belgium

© Copyright 2025. All Rights Reserved by MedPath